SNP 820
Alternative Names: Acetaminophen antidote - Sinew Pharma; SNP-820; TYNADOTELatest Information Update: 06 Apr 2023
At a glance
- Originator Sinew Pharma
- Developer Sinew Pharma; Taipei Veterans General Hospital
- Class Antidotes; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Liver disorders
Most Recent Events
- 06 Apr 2023 The Taiwanese FDA approves a phase II trial for Liver disorders in Taiwan, prior to April 2023 (Sinew Pharma pipeline, April 2023)
- 04 Oct 2022 Sinew Pharma plans a phase II trial for Liver disorder (NCT05557448)